Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fanregratinib · HMPL-453

Small molecule · Inhibitor of fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3) · developed by Hutchmed

Phase 2/3 Most advanced trial
HCM Developer
2 Registered trials

What is Fanregratinib?

Fanregratinib (HMPL-453) is an orally bioavailable small molecule that binds and inhibits fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3, blocking FGFR-related signal transduction and proliferation in FGFR-overexpressing tumor cells. It is being studied in advanced intrahepatic cholangiocarcinoma and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HMPL-453
Drug type
Small molecule
Targets
fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2), fibroblast growth factor receptor 3 (FGFR3)
Mechanism
Inhibitor of fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3)
Pathways
FGFR signal transduction, cell proliferation
Therapy area
Oncology
Developer
Hutchmed (HCM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
8RWL2B2CLS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04353375 Phase 2/3 Advanced Intrahepatic Cholangiocarcinoma Recruiting HCM
NCT07697157 Phase 1 Health, Subjective Completed HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Intrahepatic CholangiocarcinomaSolid Tumor, AdultHealth, Subjective

Other drugs acting on FGFR1 / FGFR2 / FGFR3

More from Hutchmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.

Follow HCM, the company behind Fanregratinib

See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HCM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.